The pharmacology of the parkinsonian syndrome producing neurotoxin MPTP (1–methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine) and structurally related compounds

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Medicinal research reviews (Print)

• Publication date

  1986-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/med.2610060402PMID 3534484
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Melanin affinity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, an inducer of chronic parkinsonism in humans.

  2009cited by this paper
• Biochemical and functional evidence for a marked dopamine releasing action of N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (NMPTP) in mouse brain

  2005cited by this paper
• Transport of Leucine‐Enkephalin Across the Blood‐Brain Barrier in the Perfused Guinea Pig Brain

  1987cited by this paper
• MPTP causes a non-reversible depression of synaptic transmission in mouse neostriatal brain slice.

  1986cited by this paper
• Goodman and Gilman's the Pharmacological Basis of Therapeutics

  1986cited by this paper
• Quantification of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion in brain tissue by gas chromatography/mass spectrometry.

  1986cited by this paper
• MPTP, a neurotoxin producing a Parkinsonian syndrome

  1986cited by this paper
• Registry of Toxic Effects of Chemical Substances

  1986cited by this paper
• The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.

  1985cited by this paper
• Studies on the 1-methyl-4-phenyl-2,3-dihydropyridinium species 2,3-MPDP+, the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1985cited by this paper
• Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.

  1985cited by this paper
• Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.

  1985cited by this paper
• Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease

  1985cited by this paper
• Neurology: Predicting Parkinson's disease

  1985cited by this paper
• MPTP-like molecules and Parkinson's disease.

  1985cited by this paper
• Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1985cited by this paper
• Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse.

  1985cited by this paper
• The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals.

  1985cited by this paper
• 1 ‐Methyl‐4‐Phenyl‐ 1,2,3,6‐Tetrahydropyridine: Correspondence of Its Binding Sites to Monoamine Oxidase in Rat Brain, and Inhibition of Dopamine Oxidative Deamination In Vivo and In Vitro

  1985cited by this paper
• Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

  1985cited by this paper
• Effects of amfonelic acid, alpha-methyltyrosine, Ro 4-1284 and haloperidol pretreatment on the depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.

  1985cited by this paper
• Production in nature of compound resembling methylphenyltetrahydropyridine, a possible cause of Parkinson's disease.

  1985cited by this paper
• Conversion of the neurotoxic precursor 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine into its pyridinium metabolite by human platelet monoamine oxidase type B.

  1985cited by this paper
• Distinct monoamine oxidase A and B populations in primate brain.

  1985cited by this paper
• Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1985cited by this paper
• The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1985cited by this paper
• Central and peripheral catecholamine depletion by 1-methyl-4-phenyl-tetrahydropyridine (MPTP) in rodents.

  1985cited by this paper
• Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects.

  1985cited by this paper
• Neurochemical and Histochemical Characterization of Neurotoxic Effects of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine on Brain Catecholamine Neurones in the Mouse

  1985cited by this paper
• β-Carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): Endogenous factors underlying idiopathic parkinsonism?

  1985cited by this paper
• 1-Methyl-4-phenylpyridine (MPP+) is toxic to mesencephalic dopamine neurons in culture.

  1985cited by this paper
• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does not destroy nigrostriatal neurons in the scorbutic guinea pig.

  1985cited by this paper
• The influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat.

  1985cited by this paper
• Metabolism of the neurotoxin in MPTP by human liver monoamine oxidase B

  1985cited by this paper
• Aetiology of Parkinson's disease.

  1985cited by this paper
• Cocaine blocks the dopamine depletion induced by MPTP.

  1985cited by this paper
• Catecholamine-uptake inhibitors prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain.

  1985cited by this paper
• MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study.

  1985cited by this paper
• Further insight into the mode of action of the neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)

  1985cited by this paper
• HPLC-assay with electrochemical detection for the neurotoxin MPTP, its metabolite MPP+ and MPTP-analogues in biological samples after purification over Sephadex G10.

  1985cited by this paper
• New amphibian models for the study of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1985cited by this paper
• Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity?

  1985cited by this paper
• Failure of SKF 38393‐A to relieve parkinsonian symptoms induced by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine in the marmoset

  1985cited by this paper
• Effects of 1‐Methyl‐4‐Phenyl‐1,2,5,6‐Tetrahydropyridine and Related Compounds on the Uptake of [3H]3,4‐Dihydroxyphenylethylamine and [3H]5‐Hydroxytryptamine in Neostriatal Synaptosomal Preparations

  1985cited by this paper
• In vitro oxidation of MPTP by primate neural tissue: A potential model of MPTP neurotoxicity.

  1985cited by this paper
• Synthesis and dihydropteridine reductase inhibitory effects of potential metabolites of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1985cited by this paper
• Localization in rat brain of binding sites for parkinsonian toxin MPTP: similarities with [3H]pargyline binding to monoamine oxidase.

  1985cited by this paper
• Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1985cited by this paper
• Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by liver homogenate fractions.

  1985cited by this paper
• Neurological consequence of industrial exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1985cited by this paper
• Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: relationships between monoamine oxidase, MPTP metabolism and neurotoxicity.

  1985cited by this paper
• Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)

  1985cited by this paper
• MPTP neurotoxicity: an overview and characterization of phases of toxicity.

  1985cited by this paper
• Reversible inhibition and mechanism-based irreversible inactivation of monoamine oxidases by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1985cited by this paper
• Deprenyl selectively inhibits [3H]MPTP binding sites in monkey brain.

  1985cited by this paper
• Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and several of its analogues on the dopaminergic nigrostriatal pathway in mice.

  1985cited by this paper
• Studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1985cited by this paper
• Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys.

  1985cited by this paper
• [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].

  1985cited by this paper
• Aza Diels-Alder reactions in aqueous solution: cyclocondensation of dienes with simple iminium salts generated under Mannich conditions

  1985cited by this paper
• Predicting Parkinson's disease.

  1985cited by this paper
• Benztropine inhibits toxicity of MPTP in mice.

  1985cited by this paper
• 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra.

  1984cited by this paper
• Inhibition of dihydropteridine reductase by novel 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs.

  1984cited by this paper
• Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse liver preparations.

  1984cited by this paper
• Chronic parkinsonism secondary to intranasal administration of a product of meperidine-analogue synthesis.

  1984cited by this paper
• Oxy-radical toxicity in catecholamine neurons.

  1984cited by this paper
• N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects locomotor activity without producing a nigrostriatal lesion in the rat.

  1984cited by this paper
• Parkinson's disease: Clues to aetiology from a toxin

  1984cited by this paper
• Pargyline prevents MPTP-induced parkinsonism in primates.

  1984cited by this paper
• High-affinity binding sites for [3H]MPTP may correspond to monamine oxidase.

  1984cited by this paper
• Primate model of Parkinson's disease: alterations in multiple opioid systems in the basal ganglia.

  1984cited by this paper
• Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey.

  1984cited by this paper
• Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey.

  1984cited by this paper
• Parkinsonism Induced By 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP): Implications for Treatment and the Pathogenesis of Parkinson’s Disease

  1984cited by this paper
• Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

  1984cited by this paper
• Luminescence spectra of harmine, harmaline, reserpiline and 3-dehydroreserpines

  1984cited by this paper
• The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease.

  1984cited by this paper
• Effects of N-substituted phenyltetrahydropyridines on cerebral high-affinity synaptosomal uptake of dopamine and other monoamines in several mammalian species.

  1984cited by this paper
• Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism

  1984cited by this paper
• Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

  1984cited by this paper
• Acute administration of 1-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a compound producing parkinsonism in humans, stimulates [2-14C]deoxyglucose uptake in the regions of the catecholaminergic cell bodies in the rat and guinea pig brains.

  1984cited by this paper
• Conversion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp) and its 5-methyl analog into pyridinium salts†

  1984cited by this paper
• Recent physiological and pathophysiological aspects of Parkinsonian movement disorders.

  1984cited by this paper
• 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine destroys dopamine neurons in explants of rat embryo mesencephalon.

  1984cited by this paper
• Inhibition of dopamine uptake by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a cause of parkinsonism.

  1984cited by this paper
• Drug-induced parkinsonism in the elderly.

  1984cited by this paper
• The Neurotoxicity of 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in the Monkey and Man

  1984cited by this paper
• Inhibition of [3H] MPTP binding to rat brain by pargyline.

  1984cited by this paper
• Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat.

  1984cited by this paper
• In vitro release of tritiated monoamines from rat CNS tissue by the neurotoxic compound 1-methyl-phenyl-tetrahydropyridine.

  1984cited by this paper
• Quantitative autoradiography of [3H]MPTP binding sites in rat brain.

  1984cited by this paper
• PRESIDENT'S MESSAGE: ACS and the Future

  1984cited by this paper
• Assessment of the opiate properties of two constituents of a toxic illicit drug mixture.

  1984cited by this paper
• Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

  1984cited by this paper
• Hydroxyl radical production from hydrogen peroxide and enzymatically generated paraquat radicals: catalytic requirements and oxygen dependence.

  1984cited by this paper
• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.

  1984cited by this paper
• Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain.

  1984cited by this paper
• N-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) causes destruction of the nigrostriatal but not the mesolimbic dopamine system in the monkey.

  1984cited by this paper
• Movement disorders with neuroleptic drug treatment.

  1984cited by this paper

• Therapeutic Effects of Noninvasive Electrical Stimulation in Combination Transplantation of Human Adipose‐Derived Stem Cells‐Derived Dopaminergic Neuron on the Monkey Model of Parkinson's Disease

  2026cites this paper
• Decreased Mcl-1 protein level in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.

  2018cites this paper
• Continuous MPTP intoxication in the Göttingen minipig results in chronic parkinsonian deficits.

  2016cites this paper
• Chapter 5 – Enzyme Inhibition and Inactivation

  2014cites this paper
• RGS proteins in experimental Parkinsonism and L-DOPA-induced dyskinesia

  2012cites this paper
• Nonspecific Methods for the Destruction of Hazardous Chemicals in the Laboratory

  2012cites this paper
• The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys

  2011cites this paper
• Synthesis of 5-(3,4-dichlorophenyl)-4-[(methyloxy)methyl]-2-azabicyclo[3.2.1]octane derivatives as constrained aryl-piperidines with activity as triple re-uptake inhibitors

  2010cites this paper
• Neuroprotective compounds and innovative therapeutic strategies for Parkinson's disease: experimental and clinical studies

  2009cites this paper
• Protective effect of captopril and enalaprilat, angiotensin-converting enzyme inhibitors, on para-nonylphenol-induced *OH generation and dopamine efflux in rat striatum.

  2008cites this paper
• Effects of haloperidol and its pyridinium metabolite on plasma membrane permeability and fluidity in the rat brain.

  2007influential citation
• Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?

  2006cites this paper
• Neurotoxic damage to the nigrostriatal system in rats following intranigral administration of MPDP+ and MPP+

  2005cites this paper
• Experimental and Clinical Studies

  2005cites this paper
• Delivery of transgenically modified adult bone marrow cells to the rodent central nervous system

  2004cites this paper
• Strategies for investigation and control of process- and degradation-related impurities

  2004cites this paper
• Enzyme Inhibition and Inactivation

  2004cites this paper
• ESTUDO DE MECANISMOS DOPAMINÉRGICOS, NICOTÍNICOS E ADENOSINÉRGICOS EM MODELOS DE PARKINSONISMO INDUZIDO POR 6-HIDROXIDOPAMINA E MPTP EM RATOS

  2004cites this paper
• Synthesis and in vitro biological evaluation of fluoro-substituted-4-phenyl-1,2,3,6-tetrahydropyridines as monoamine oxidase B substrates.

  2003cites this paper
• Influence of lipophilicity on the interactions of N-alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and their positively charged N-alkyl-4-phenylpyridinium metabolites with cytochrome P450 2D6.

  2003cites this paper
• From drugs of abuse to parkinsonism. The MPTP mouse model of Parkinson's disease.

  2003cites this paper
• Analysis of the Metabolism of Haloperidol and Its Neurotoxic Pyridinium Metabolite in Patients with Drug-Induced Parkinsonism

  2001cites this paper
• Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia.

  2001cites this paper
• Protection of nigral neurons by GDNF-engineered marrow cell transplantation.

  2001cites this paper
• Suppression of paraquat-induced wet dog shakes by nitric oxide synthase inhibitors in rats.

  2000cites this paper
• Reserpine prevents hydroxyl radical formation by MPP+ in rat striatum.

  1999cites this paper
• Protective effect of imidaprilat, a new angiotensin-converting enzyme inhibitor against 1-methyl-4-phenylpyridinium ion-induced *OH generation in rat striatum.

  1999cites this paper
• Protective effect of histidine on MPP+-induced hydroxyl radical generation in rat striatum.

  1999cites this paper
• Studies on the monoamine oxidase-B-catalyzed biotransformation of 4-azaaryl-1-methyl-1,2,3,6-tetrahydropyridine derivatives.

  1999cites this paper
• Haloperidol-Derived Pyridinium Metabolites

  1998cites this paper
• MAO — The Mother of all Amine Oxidases

  1998cites this paper
• Orphan neurones and amine excess: the functional neuropathology of Parkinsonism and neuropsychiatric disease.

  1998cites this paper
• Monoamine oxidases and related amine oxidases as phase I enzymes in the metabolism of xenobiotics.

  1998cites this paper
• Effect of the haloperidol tetrahydropyridine metabolite 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6- tetrahydropyridine on dopamine receptor and transporter binding. A nonhuman primate 123I-iodobenzamide and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane single photon emission com

  1997cites this paper
• Long-term treatment with the tetrahydropyridine analog (HPTP) of haloperidol influences dopamine ligand binding in baboon brain. An [123I]iodobenzamide (IBZM) SPECT study.

  1996cites this paper
• Synthesis and 5HT modulating activity of stereoisomers of 3-phenoxymethyl-4-phenylpiperidines.

  1996cites this paper
• ILLUMINATION OF THERAPEUTICS BY TOXICOLOGY: A PERSONAL VIEW *

  1996cites this paper
• Synthesis of trans-3,4-Dimethyl-4-(3-hydroxyphenyl)piperidine Opioid Antagonists: Application of the Cis-Thermal Elimination of Carbonates to Alkaloid Synthesis.

  1996cites this paper
• Comparison of brain dopamine depletion induced by low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in young and aged rats.

  1994cites this paper
• MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies.

  1994cites this paper
• Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice.

  1994cites this paper
• Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia

  1994cites this paper
• Contribution of amine oxidases to the metabolism of xenobiotics.

  1994cites this paper
• 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies.

  1994cites this paper
• Paradoxical sleep deprivatory effect of a single low dose of MPTP which did not produce dopaminergic cell loss

  1993cites this paper
• The History of l-Deprenyl

  1993cites this paper
• Identification of a pyridinium metabolite in human urine following a single oral dose of 1-[2-[bis[4-(trifluoromethyl)phenyl]methoxy]ethyl]- 1,2,5,6-tetrahydro-3-pyridinecarboxylic acid monohydrochloride, a gamma-aminobutyric acid uptake inhibitor.

  1993cites this paper
• Trophism, transplantation, and animal models of Parkinson's disease.

  1993cites this paper
• L-deprenyl confers specific protection against MPTP-induced Parkinson's disease-like movement disorder in the goldfish.

  1993cites this paper
• In vivo release of dopamine by perfusion of 1-methyl-4-phenylpyridinium ion in the striatum with a microdialysis technique.

  1992cites this paper
• A parkinsonian syndrome induced in the goldfish by the neurotoxin MPTP

  1992cites this paper
• Effects of MPTP and vitamin E treatments on immune function in mice.

  1992cites this paper
• Search for neurotoxins structurally related to 1-methyl-4-phenylpyridine (MPP+) in the pathogenesis of Parkinson's disease.

  1992cites this paper
• Sensitivity of the generator of spontaneous motility in chick embryos to the acute and chronic administration of MPTP.

  1992cites this paper
• CHAPTER 5: – Enzyme Inhibition and Inactivation

  1992cites this paper
• Chronic administration of nicotine fails to alter the MPTP-induced neurotoxicity in mice.

  1991cites this paper
• 12 - Unilateral MPTP-Lesioned Monkey as an Animal Model for Parkinson's Disease

  1991cites this paper
• Age-related changes in locomotor behavior induced by MPTP in rats.

  1991cites this paper
• 2-amino-3-(methylamino)-propanoic acid (BMAA) pharmacokinetics and blood-brain barrier permeability in the rat.

  1991cites this paper
• Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol.

  1991cites this paper
• Histological and ultrastructural evidence that D-amphetamine causes degeneration in neostriatum and frontal cortex of rats.

  1990cites this paper
• The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism.

  1990cites this paper
• Inhibition of mitochondrial respiration by analogues of the dopaminergic neurotoxin 1-methyl-4-phenylpyridinium: structural requirements for accumulation-dependent enhanced inhibitory potency on intact mitochondria.

  1990cites this paper
• 2‐Amino‐3‐(methylamino)‐propanoic acid (BMAA) in cycad flour

  1990cites this paper
• Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats.

  1990cites this paper
• Midbrain micromass cultures: a model for studies of teratogenic and sub-teratogenic effects on CNS development.

  1990cites this paper
• Tissue concentrations of MPTP and MPP+ after administration of lethal and sublethal doses of MPTP to mice.

  1990cites this paper
• Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism.

  1990cites this paper
• 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Induced neurotoxicity in the rat: Characterization and age‐dependent effects

  1990cites this paper
• In Vitro Testing of Neurotoxicity

  1990cites this paper
• Sodium diethyldithiocarbamate protects against the MPTP-induced inhibition of immune responses in mice.

  1989cites this paper
• Progress in Parkinson Research

  1989cites this paper
• Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity.

  1989cites this paper
• Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1989cites this paper
• Possible catabolism of paraquat in mouse brain microsomes.

  1989cites this paper
• Metabolic studies on the nigrostriatal toxin MPTP and its MAO B generated dihydropyridinium metabolite MPDP+.

  1988cites this paper
• A Biological Evaluation Of Some 2′-Substituted Analogs Of MPTP

  1988cites this paper
• Recommended safe practices for using the neurotoxin MPTP in animal experiments.

  1988cites this paper
• Platelets as a model for neurones?

  1988cites this paper
• In vivo assessment of neurotransmitter biochemistry in humans.

  1988cites this paper
• MPP+-induced efflux of dopamine and lactate from rat striatum have similar time courses as shown by in vivo brain dialysis.

  1988cites this paper
• Synthesis and analgesic properties of N-substituted trans-4a-aryldecahydroisoquinolines.

  1988cites this paper
• Inhibition of mitochondrial respiration by analogs of 4-phenylpyridine and 1-methyl-4-phenylpyridinium cation (MPP+), the neurotoxic metabolite of MPTP.

  1987cites this paper
• MPP+ (1-methyl-4-phenylpyridine) is a neurotoxin to dopamine-, norepinephrine- and serotonin-containing neurons.

  1987cites this paper
• Model study on the bioreduction of paraquat, MPP+, and analogs. Evidence against a "redox cycling" mechanism in MPTP neurotoxicity.

  1987cites this paper